Revisiting Adjuvant Hormone Therapy in Premenopausal Women With Breast Cancer: Escalation and De-Escalation

摘要

The National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) have published guidelines for locoregional breast cancer that suggest in premenopausal women, clinicians should give adjuvant tamoxifen for 5 years in low-risk breast cancer, extend hormone therapy in high-risk patients, and consider adding ovarian function suppression (OFS) in patients with a higher risk of relapse. However, the guidelines are relatively ambiguous about patient selection.1'2 The article by Sella et al3 is of great value in guiding clinical decision making. However, some points remain to be elucidated.